Iovance Biotherapeutics (IOVA) Provides Regulatory Update for Lifileucel Potency Assays, BLA Submission Now Expected H1 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Iovanace Biotherapeutics (IOVA) Has Strong Cash Cushion Even as CEO Exit Adds to Uncertainties - Mizuho
May 19, 2021 12:42 PM EDTMizuho Securities analyst Mara Goldstein weighed in on Iovanace Biotherapeutics (NASDAQ: IOVA) after the company announced that Maria Fardis, Ph.D. will resign as President and CEO of the company following today's regulatory setback.
"The commercial potential for lifileucel remains but the question... More
Iovanace Biotherapeutics (IOVA) PT Lowered to $33 at Stifel on BLA Push
May 19, 2021 8:05 AM EDTStifel analyst Benjamin Burnett lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $33.00 (from $49.00) while maintaining a Buy rating.
The analyst commented, "Although yesterday's update has us scratching our heads and leaves us with a number of outstanding questions, we remain... More
Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at Chardan Capital Markets on BLA Delay
May 19, 2021 7:58 AM EDTChardan Capital Markets analyst Geulah Livshits lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $51.00 (from $54.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, after market close, Iovance Biotherapeutics announced revised guidance for BLA filing on tumor infiltrating lymphocyte (TIL)... More
